Literature DB >> 26216961

Microbiota regulates type 1 diabetes through Toll-like receptors.

Michael P Burrows1, Pavel Volchkov1, Koichi S Kobayashi2, Alexander V Chervonsky3.   

Abstract

Deletion of the innate immune adaptor myeloid differentiation primary response gene 88 (MyD88) in the nonobese diabetic (NOD) mouse model of type 1 diabetes (T1D) results in microbiota-dependent protection from the disease: MyD88-negative mice in germ-free (GF), but not in specific pathogen-free conditions develop the disease. These results could be explained by expansion of particular protective bacteria ("specific lineage hypothesis") or by dominance of negative (tolerizing) signaling over proinflammatory signaling ("balanced signal hypothesis") in mutant mice. Here we found that colonization of GF mice with a variety of intestinal bacteria was capable of reducing T1D in MyD88-negative (but not wild-type NOD mice), favoring the balanced signal hypothesis. However, the receptors and signaling pathways involved in prevention or facilitation of the disease remained unknown. The protective signals triggered by the microbiota were revealed by testing NOD mice lacking MyD88 in combination with knockouts of several critical components of innate immune sensing for development of T1D. Only MyD88- and TIR-domain containing adapter inducing IFN β (TRIF) double deficient NOD mice developed the disease. Thus, TRIF signaling (likely downstream of Toll-like receptor 4, TLR4) serves as one of the microbiota-induced tolerizing pathways. At the same time another TLR (TLR2) provided prodiabetic signaling by controlling the microbiota, as reduction in T1D incidence caused by TLR2 deletion was reversed in GF TLR2-negative mice. Our results support the balanced signal hypothesis, in which microbes provide signals that both promote and inhibit autoimmunity by signaling through different receptors, including receptors of the TLR family.

Entities:  

Keywords:  Toll-like receptors; commensal microbiota; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26216961      PMCID: PMC4538618          DOI: 10.1073/pnas.1508740112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.

Authors:  Karl S Lang; Mike Recher; Tobias Junt; Alexander A Navarini; Nicola L Harris; Stefan Freigang; Bernhard Odermatt; Curdin Conrad; Lars M Ittner; Stefan Bauer; Sanjiv A Luther; Satoshi Uematsu; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal:  Nat Med       Date:  2005-01-16       Impact factor: 53.440

2.  Human genetics shape the gut microbiome.

Authors:  Julia K Goodrich; Jillian L Waters; Angela C Poole; Jessica L Sutter; Omry Koren; Ran Blekhman; Michelle Beaumont; William Van Treuren; Rob Knight; Jordana T Bell; Timothy D Spector; Andrew G Clark; Ruth E Ley
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

3.  Inhibition of autoimmune diabetes by TLR2 tolerance.

Authors:  Do-Hoon Kim; June-Chul Lee; Sunshin Kim; Seung Hoon Oh; Moon-Kyu Lee; Kwang-Won Kim; Myung-Shik Lee
Journal:  J Immunol       Date:  2011-10-12       Impact factor: 5.422

4.  Danger-free autoimmune disease in Aire-deficient mice.

Authors:  Daniel H D Gray; Irina Gavanescu; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-08       Impact factor: 11.205

5.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

Review 6.  Microbiota and autoimmunity.

Authors:  Alexander V Chervonsky
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

7.  A microbial symbiosis factor prevents intestinal inflammatory disease.

Authors:  Sarkis K Mazmanian; June L Round; Dennis L Kasper
Journal:  Nature       Date:  2008-05-29       Impact factor: 49.962

8.  The role of Toll-like receptors 3 and 9 in the development of autoimmune diabetes in NOD mice.

Authors:  F Susan Wong; Changyun Hu; Li Zhang; Wei Du; Lena Alexopoulou; Richard A Flavell; Li Wen
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Authors:  Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky
Journal:  Nature       Date:  2008-09-21       Impact factor: 49.962

10.  Toll-like receptor 4 deficiency accelerates the development of insulin-deficient diabetes in non-obese diabetic mice.

Authors:  Elke Gülden; Masaru Ihira; Atsushi Ohashi; Anna Lena Reinbeck; Marina A Freudenberg; Hubert Kolb; Volker Burkart
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more
  67 in total

1.  Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice.

Authors:  Camilla H F Hansen; Christian S Larsen; Henriette O Petersson; Line F Zachariassen; Andreas Vegge; Charlotte Lauridsen; Witold Kot; Łukasz Krych; Dennis S Nielsen; Axel K Hansen
Journal:  Diabetologia       Date:  2019-05-28       Impact factor: 10.122

Review 2.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

Review 3.  Gastrointestinal Barrier Breakdown and Adipose Tissue Inflammation.

Authors:  Lediya Cheru; Charles F Saylor; Janet Lo
Journal:  Curr Obes Rep       Date:  2019-06

Review 4.  The crucial role of early-life gut microbiota in the development of type 1 diabetes.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Acta Diabetol       Date:  2020-07-25       Impact factor: 4.280

Review 5.  Antibiotics, gut microbiota, environment in early life and type 1 diabetes.

Authors:  Youjia Hu; F Susan Wong; Li Wen
Journal:  Pharmacol Res       Date:  2017-02-07       Impact factor: 7.658

6.  Modulation of the immune system by the gut microbiota in the development of type 1 diabetes.

Authors:  James A Pearson; Andrew Agriantonis; F Susan Wong; Li Wen
Journal:  Hum Vaccin Immunother       Date:  2018-09-19       Impact factor: 3.452

7.  Papio spp. Colon microbiome and its link to obesity in pregnancy.

Authors:  XuanJi Li; Christopher Rensing; William L Taylor; Caitlin Costelle; Asker Daniel Brejnrod; Robert J Ferry; Paul B Higgins; Franco Folli; Kameswara Rao Kottapalli; Gene B Hubbard; Edward J Dick; Shibu Yooseph; Karen E Nelson; Natalia Schlabritz-Loutsevitch
Journal:  J Med Primatol       Date:  2018-07-24       Impact factor: 0.667

Review 8.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

9.  Differential expression and release of exosomal miRNAs by human islets under inflammatory and hypoxic stress.

Authors:  Prathab Balaji Saravanan; Srividya Vasu; Gumpei Yoshimatsu; Carly M Darden; Xuan Wang; Jinghua Gu; Michael C Lawrence; Bashoo Naziruddin
Journal:  Diabetologia       Date:  2019-08-01       Impact factor: 10.122

Review 10.  Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases.

Authors:  Zejun Zhou; Miao Ding; Lei Huang; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2016-09-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.